The chairman of the board of Memorial Sloan Kettering Cancer Center (MSKCC) told the hospital’s staff that the former chief medical officer, José Baselga, MD, had “crossed lines” and had gone “off the reservation” in his outside dealings with health and drug companies; more than any other industry, the pharmaceutical industry benefits from a patent strategy that allows small changes in existing drugs to confer continued patent protection; public health officials are worried that the latest Ebola outbreak in the Democratic Republic of the Congo may be spinning beyond their control and could spill over into Uganda and Rwanda.
The chairman of the board of Memorial Sloan Kettering Cancer Center told the hospital’s staff that the former chief medical officer, José Baselga, MD, had “crossed lines” and had gone “off the reservation” in his outside dealings with health and drug companies. In an email obtained inadvertently by The New York Times, the comments by Douglas A. Warner III, the chairman, as well as Craig B. Thompson, MD, the chief executive, went beyond previous statements about the Baselga. The hospital previously had said that Baselga followed internal policies and had just failed to disclose his industry affiliations in some medical journal articles.
More than any other industry, the pharmaceutical industry benefits from a patent strategy that allows small changes in existing drugs to confer continued patent protection, Kaiser Health News reported. The series of secondary protective patents is a tactic critics call “evergreening” or “product-hopping.” Attempts to change the patent system have intensified as drug prices continue to rise.
Public health officials are worried that the latest Ebola outbreak in the Democratic Republic of the Congo may be spinning beyond their control and could spill over into Uganda and Rwanda, STAT News reported. Ebola response teams are facing restrictions on their movements in a conflict zone, and if response teams lose sight of where the virus goes, it could spread undetected and unchecked in places where they cannot safely travel. To date, there have been 161 cases and 105 deaths.
Diagnostic Oversights Limit Luspatercept Benefits in MDS
May 8th 2024Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen